

Questions for categories: **Medical Devices**

Nano Retina Ltd. Presenting the NR600 System

- **Investment Rational**
Nano Retina focuses on restoration of visual capabilities to blind people due to retinal degenerative disease (AMD, RP, DR, etc.) by prosthetic implantable device, and is currently in feasibility clinical study stage. The company is part of Rainbow Medical Ltd. portfolio leading technology companies.
- **Business Strategy**
The company has initiated a first-in-human clinical study in Europe and Israel to demonstrate safety and probable benefit. Pivotal study activity is in progress with the FDA under HUD path toward PMA approval and CE mark. Hand in hand with the high prevalence and growth of retinal degenerative diseases, the treatment costs are soaring. It is estimated that the global cost of visual impairment due to AMD is \$343 billion, including \$255 billion in direct health care costs
- **Core Technology**
Tissue penetrating micro electrode array with embedded microchips powered by external infrared source that activate the neural pathway in the eye. In the US and EU the face value of reimbursement to similar treatments is 140K \$.
- **Product Profile/Pipeline**
The NR600 system is a novel wireless retinal prosthetic device which transforms the visual image into an electrical signal and transmits it via 3D electrodes to the functional cells in the inner retina to generate image perception in blind patients. To date, there's no available therapy in the market. The company expect early sales in 2025.
- **What's Next?**
The R&D and clinical teams are continuously searching for design improvement and rehabilitation programs that will refine the image perception that will enable independency to the blinds in their daily life activity.